Baudax Bio to Present at the Oppenheimer 32nd Annual Healthcare Conference
March 10 2022 - 7:00AM
Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on
commercializing and developing innovative products for acute care
settings, announced that Gerri Henwood, the Company’s President and
Chief Executive Officer, will present at the Oppenheimer 32nd
Annual Healthcare Conference on Tuesday, March 15, 2022 at 2:40
p.m. Eastern Time.
A live webcast of the presentation will be
available on the “Events” page within the investors section of the
Baudax Bio website at https://www.baudaxbio.com/news-and-investors.
A replay will be available on the Baudax Bio website for a period
of 30 days following the event.
About Baudax Bio
Baudax Bio is a pharmaceutical company focused
on commercializing and developing innovative products for acute
care settings. ANJESO is the first and only 24-hour, intravenous
(IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for
the management of moderate to severe pain. In addition to ANJESO,
Baudax Bio has a pipeline of other innovative pharmaceutical assets
including two novel neuromuscular blocking agents (NMBs) and a
proprietary chemical reversal agent specific to these NMBs. For
more information, please visit www.baudaxbio.com.
CONTACT:
Investor Relations Contact:
Argot PartnersSam Martin / Kaela Ilami(212)
600-1902baudaxbio@argotpartners.com
Media Contact:
Argot PartnersDavid Rosen(212)
600-1902david.rosen@argotpartners.com
Baudax Bio (NASDAQ:BXRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Baudax Bio (NASDAQ:BXRX)
Historical Stock Chart
From Sep 2023 to Sep 2024